Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (NASDAQ: OM) is a medical technology company focused on transforming dialysis with its Tablo Hemodialysis System, and its news flow reflects both business performance and developments in kidney care. Company press releases regularly describe Outset as pioneering a first-of-its-kind technology designed to reduce the cost and complexity of dialysis across hospital and home settings.
News updates for OM commonly include quarterly financial results, where Outset reports product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and cash balances. These releases may also include revised or updated annual revenue guidance and commentary on progress toward financial objectives.
Investors and clinicians following Outset Medical can also expect clinical and research news. The company has highlighted data from large numbers of Tablo treatments across hundreds of facilities, as well as multi-year results from hospitals that have insourced dialysis service lines using Tablo. Such announcements focus on clinical outcomes, operational metrics, and the implications of insourced dialysis models for acute-care facilities.
Outset’s news stream further covers strategic and corporate developments, such as board appointments, the creation of clinical leadership roles, and collaborations with dialysis providers to expand access to home hemodialysis using Tablo. The company also announces presentations at major healthcare and investor conferences, where management discusses its technology, business strategy, and financial performance.
This OM news page aggregates these releases so readers can follow Outset Medical’s earnings reports, clinical evidence updates, collaborations, and corporate milestones in one place.
Outset Medical (Nasdaq: OM) reported inducement equity awards approved by its Compensation Committee under Nasdaq Listing Rule 5635(c)(4) for two new hires. The Company granted 96,000 RSUs to Derick Elliott, EVP of Commercial, and 10,380 RSUs to another new non-executive employee.
The RSUs vest over three years: 33.33% at the one-year anniversary and the remaining 66.67% in quarterly installments thereafter, subject to continued service and usual acceleration or forfeiture terms.
Outset Medical (Nasdaq: OM) appointed Derick Elliott as Executive Vice President of Commercial, effective April 6, 2026. Elliott will lead commercial teams across acute, post-acute and home care and report to Chair and CEO Leslie Trigg. He brings 30+ years of sales and marketing experience from Stryker, Cardinal Health and SpendMend.
The company noted Elliott’s experience with capital equipment, software, EMR connectivity and recurring revenue and cited nearly 1,000 acute facilities using Tablo.
Outset Medical (Nasdaq: OM) reported fourth-quarter and full-year 2025 results. Revenue was $28.9M in Q4 and $119.5M for 2025, up 5% year-over-year. Recurring revenue grew 6% to $88.7M. Gross margin expanded ~500–600 bps to 42.4% in Q4 and 39.1% for 2025. Year-end cash totaled $173M. The company received FDA clearance for its next-generation Tablo platform, expected to launch in Q2 2026. 2026 revenue guidance is $125M–$130M with non-GAAP gross margin in the low- to mid-40% range.
Outset Medical (Nasdaq: OM) announced FDA 510(k) clearance for its next-generation Tablo hemodialysis platform on Jan 27, 2026. The platform is the first dialysis system cleared to meet the FDA's June 2025 guidance on medical device cybersecurity and includes hardware, operating system, and software enhancements to improve reliability, performance, and durability. The next-generation Tablo is expected to begin shipping to customers in Q2 2026, and existing Tablo users will be eligible for an upgrade to the new cybersecurity platform.
Outset Medical (Nasdaq: OM) will report fourth quarter and full-year 2025 financial results after market close on Wednesday, February 11, 2026. A conference call with Leslie Trigg, Chair and CEO, and Renee Gaeta, CFO, will be held the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss financial and operating results. Interested participants must register online to receive dial-in numbers and a unique PIN, and are encouraged to register at least 15 minutes before the call. A live and archived webcast will be available in the Investors section of the company's website.
Outset Medical (Nasdaq: OM) reported unaudited revenue of $28.9M for Q4 and $119.5M for full-year 2025, a 5% increase versus $113.7M in 2024. The company said more than 1,000 care sites have insourced dialysis on Tablo, performing roughly 1M treatments per year and >3M cumulative treatments. Year-end cash and short-term investments totaled $173M. Net cash used in operations for 2025 was reported as below $50M versus $116M in 2024. Outset announced a board appointment: Karen N. Prange joins the board and Compensation Committee, replacing Andrea Saia. Management cited a strong backlog and growing pipeline entering 2026.
Outset Medical (Nasdaq: OM) announced that Chair & CEO Leslie Trigg will present at the 44th annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 4:30 p.m. PT. A live webcast and archived replay will be available in the Investors section of Outset Medical's website at https://investors.outsetmedical.com/.
This presentation offers investors a scheduled opportunity to hear company updates directly from management and access a recorded webcast for later review.
Outset Medical (Nasdaq: OM) reported third-quarter 2025 results for the period ended September 30, 2025. Revenue was $29.4 million, up 3% year-over-year, driven by an 8% rise in Tablo console sales and recurring revenue of $21.1 million. Gross margin improved to 39.4% (non-GAAP 39.9%), and operating expenses declined ~19% versus Q3 2024. Net loss narrowed to $17.8 million (non-GAAP loss $12.0 million). Cash and short-term investments totaled approximately $182 million at quarter-end.
The company revised 2025 revenue guidance down to $115M–$120M (from $122M–$126M) but maintained non-GAAP gross margin guidance in the high-30% range and reiterated expected cash use of less than $50M in 2025.
Outset Medical (Nasdaq: OM) reported new research from over 1 million Tablo hemodialysis treatments across ~750 facilities and 5-year results from an insourced dialysis program at a large Florida hospital presented at ASN Kidney Week 2025 (Nov 5-8).
Key findings included a 94% reduction in serious cardiac/respiratory events, sustained reductions in central-line bloodstream infections, >95% dialysis staff satisfaction, strong return on investment within 2 years, and >99% achievement of treatment goals for ~10,000 prolonged (23–24h) treatments.
Outset Medical (Nasdaq: OM) will present at the 2025 Stifel Healthcare Conference on Wednesday, November 12, 2025 at 10:40 a.m. ET.
Company management will deliver a live presentation; a live and archived webcast will be available on the Investors section of the Outset Medical website at https://investors.outsetmedical.com/.